Suppr超能文献

给马口服单剂两种长效制剂和盐酸多西环素水混悬液的药代动力学。

Pharmacokinetics of a peroral single dose of two long-acting formulations and an aqueous formulation of doxycycline hyclate in horses.

机构信息

Department of Physiology and Pharmacology, School of Veterinary Medicine, National Autonomous University of Mexico (UNAM), Av, Universidad 3000, Coyoacan Mexico City 04360, Mexico.

出版信息

Acta Vet Scand. 2013 Mar 8;55(1):21. doi: 10.1186/1751-0147-55-21.

Abstract

BACKGROUND

Doxycyline (Dox) is a semisynthetic antibacterial drug with pharmacological advantages over its parent drug (tetracycline) in the treatment of various bacterial diseases in horses. Yet, at present a horse-customized pharmaceutical formulation is not available. Based on its pharmacokinetic/pharmacodynamic (PK/PD) ratio, Dox is considered a time-dependent antibacterial drug and ideally expected to achieve sustained plasma drug concentrations both at or slightly above the minimal inhibitory concentration (MIC) level for as long as possible between dosing intervals. Hence, the objective of this study was to formulate two long-acting (LA) doxycyline hyclate (Dox-h) formulations for oral administration and define their pharmacokinetics in non-fasted adult horses to obtain better bioavailability and longer mean residence time, features needed to comply better with its pharmacokinetic/pharmacodynamic (PK/PD) ratios.

RESULTS

Pharmacokinetic parameters were determined after the oral administration of a single 10 mg/kg bolus dose of two 20% Dox-h formulations: one based on a β cyclodextrin (Dox-β) matrix and a second one on a poloxamer (Dox-pol) matrix. The results were compared with the pharmacokinetics of a single 10 mg/kg bolus oral dose of a freshly made aqueous Dox-h solution (Dox-a). Dox-pol showed the greatest values for relative bioavailability (548%); maximum serum concentration (Cmax) value was 1.3 ± 0.7 μg/mL with time to reach the Cmax (Tmax) of 5.9 ± 1.7 h, area under the curve (AUC) of 17.0 ± 2.2 μg h/ml and elimination half-life (T½ β) of 4.9 ± 1.0 h.

CONCLUSIONS

Considering a minimal inhibitory concentration MIC of 0.25 μg/mL, clinically effective plasma concentrations might be obtained for up to 24 h administering Dox-pol. This is an oral paste formulation that might optimize the use of Dox-h in horses in terms of PK/PD ratio congruency, and it is likely that it may also improve prescription compliance due to its ease of administration.

摘要

背景

多西环素(Dox)是一种半合成抗菌药物,在治疗马的各种细菌性疾病方面具有优于其母体药物(四环素)的药理学优势。然而,目前尚无针对马的定制药物制剂。基于其药代动力学/药效学(PK/PD)比值,Dox 被认为是一种时间依赖性抗菌药物,理想情况下,应在两次给药间隔之间尽可能长时间地保持血浆药物浓度维持在或略高于最低抑菌浓度(MIC)水平。因此,本研究的目的是配制两种长效(LA)盐酸多西环素(Dox-h)口服制剂,并确定其在非禁食成年马中的药代动力学特征,以获得更好的生物利用度和更长的平均驻留时间,这是更好地符合其药代动力学/药效学(PK/PD)比值的特征。

结果

单次口服 10 mg/kg 负荷剂量的两种 20% Dox-h 制剂(一种基于β环糊精(Dox-β)基质,另一种基于泊洛沙姆(Dox-pol)基质)后,确定了药代动力学参数。将结果与单次口服 10 mg/kg 负荷剂量的新鲜制备的盐酸多西环素水溶液(Dox-a)的药代动力学进行比较。Dox-pol 的相对生物利用度最高(548%);最大血清浓度(Cmax)值为 1.3±0.7 μg/mL,达峰时间(Tmax)为 5.9±1.7 h,曲线下面积(AUC)为 17.0±2.2 μg h/ml,消除半衰期(T½β)为 4.9±1.0 h。

结论

考虑到最低抑菌浓度 MIC 为 0.25 μg/mL,使用 Dox-pol 给药可能获得长达 24 小时的临床有效血浆浓度。这是一种口服糊剂制剂,可能在 PK/PD 比值一致性方面优化了多西环素在马中的使用,并且由于其易于给药,它还有可能提高处方的依从性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验